Protagonist Therapeutics (PTGX) EBITDA Margin (2017 - 2026)

Protagonist Therapeutics has reported EBITDA Margin for 10 years, with the latest figure at 6.47% in Q1 2026.

• Quarterly EBITDA Margin rose 6171.0% year-over-year to 6.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 192.36% (down 20582.0% YoY) and the FY2025 annual result came in at 343.63%, down 40184.0% from the prior year.
• EBITDA Margin advanced to 6.47% in Q1 2026 per PTGX's latest filing, from 677.09% in the prior quarter.
• Over five years, EBITDA Margin peaked at 80.92% in Q1 2024 and troughed at 4824.56% in Q2 2022.
• A 5-year average of 751.28% and a median of 379.58% in 2022 frame the typical range for EBITDA Margin.
• The widest YoY moves for EBITDA Margin: up 30605 bps in 2022, down 346112 bps in 2022.
• Over 5 years, EBITDA Margin stood at 4824.56% in 2022, then surged by 101 bps to 46.1% in 2023, then surged by 67 bps to 76.84% in 2024, then sank by 981 bps to 677.09% in 2025, then jumped by 99 bps to 6.47% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 6.47%, 677.09%, and 985.17% for Q1 2026, Q4 2025, and Q3 2025 respectively.